New combo therapy targets Hard-to-Treat breast cancer brain tumors
NCT ID NCT03483012
First seen Jan 02, 2026 · Last updated May 03, 2026 · Updated 17 times
Summary
This early-phase study tested whether combining the immunotherapy drug atezolizumab with precise radiation (stereotactic radiosurgery) could help control triple-negative breast cancer that has spread to the brain. Only 6 people took part. The goal was to see how long the cancer stayed under control and whether the treatment shrank tumors elsewhere in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.